ZA891901B - Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy - Google Patents

Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy

Info

Publication number
ZA891901B
ZA891901B ZA891901A ZA891901A ZA891901B ZA 891901 B ZA891901 B ZA 891901B ZA 891901 A ZA891901 A ZA 891901A ZA 891901 A ZA891901 A ZA 891901A ZA 891901 B ZA891901 B ZA 891901B
Authority
ZA
South Africa
Prior art keywords
treatment
side effects
effects associated
extrapyramidal side
neuroleptic therapy
Prior art date
Application number
ZA891901A
Other languages
English (en)
Inventor
Michael G Palfreyman
G Palfreyman Michael
Albert A Carr
A Carr Albert
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of ZA891901B publication Critical patent/ZA891901B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA891901A 1988-03-17 1989-03-13 Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy ZA891901B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16926988A 1988-03-17 1988-03-17

Publications (1)

Publication Number Publication Date
ZA891901B true ZA891901B (en) 1989-11-29

Family

ID=22614934

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA891901A ZA891901B (en) 1988-03-17 1989-03-13 Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy

Country Status (6)

Country Link
EP (1) EP0337136A3 (xx)
JP (1) JPH01275530A (xx)
KR (1) KR890014114A (xx)
AU (1) AU614117B2 (xx)
DK (1) DK128589A (xx)
ZA (1) ZA891901B (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US6004980A (en) * 1990-06-01 1999-12-21 Merrell Pharmaceuticals, Inc. (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
DE69105501T2 (de) * 1990-06-01 1995-04-13 Merrell Dow Pharma (+)-alpha-(2,3 dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinmethanol.
US5231099A (en) * 1991-04-15 1993-07-27 Du Pont Merck Pharmaceutical Company Use of sigma receptor antagonists to enhance the effects of antipsychotic drugs
US5618824A (en) * 1994-03-09 1997-04-08 Merrell Pharmaceuticals Inc. Treatment of obsessive-compulsive disorders with 5-HT2 antagonists
ZA9610736B (en) 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
EP0796619A1 (en) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders
US6028083A (en) * 1997-07-25 2000-02-22 Hoechst Marion Roussel, Inc. Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
US6713627B2 (en) 1998-03-13 2004-03-30 Aventis Pharmaceuticals Inc. Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
US6277864B1 (en) 1998-08-28 2001-08-21 Aventis Pharmaceuticals Inc. Use of R- +)-α-(2,3-dimethoxyphenyl-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol for the treatment of sleep disorders
US6939879B2 (en) 1998-08-28 2005-09-06 Aventis Pharmaceuticals Inc. Use of R (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of substance induced insomnia
DE102004010132A1 (de) 2004-02-27 2005-09-15 Merck Patent Gmbh Piperidinderivate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1280421C (en) * 1985-07-02 1991-02-19 Albert A. Carr 1,4-disubstituted piperidinyl derivatives
US5093341A (en) * 1987-12-17 1992-03-03 Merrell Dow Pharmaceuticals Inc. N-aralkyl piperidine derivatives useful as antithrombolytic agents

Also Published As

Publication number Publication date
KR890014114A (ko) 1989-10-21
DK128589D0 (da) 1989-03-16
AU3133889A (en) 1989-09-21
AU614117B2 (en) 1991-08-22
JPH01275530A (ja) 1989-11-06
DK128589A (da) 1989-09-18
EP0337136A2 (en) 1989-10-18
EP0337136A3 (en) 1990-09-05

Similar Documents

Publication Publication Date Title
ZA891901B (en) Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy
GB2219005B (en) Electrolytic treatment apparatus
EP0349983A3 (en) Electrolytic treatment apparatus
GB2225570B (en) Continuous treatment process
GB8718259D0 (en) Treating containers
KR0134034B1 (en) Treatment method
BG44296A1 (en) Method for chemico- thermic treatment
BG46027A1 (en) Means for parodontosys treatment
GR3003007T3 (en) Process for the treatment of alpha-calciumsulphate-hemihydrate
GB8826492D0 (en) Therapy apparatus
GB8719038D0 (en) Therapeutic method
GB8723611D0 (en) Treatment
GB8724439D0 (en) Treatment
GB8708042D0 (en) Treatment
GB8709875D0 (en) Treatment
GB8711457D0 (en) Treatment
GB8712243D0 (en) Treatment
GB8712238D0 (en) Treatment
GB8712244D0 (en) Treatment
GB8712245D0 (en) Treatment
GB8712246D0 (en) Treatment
GB8716533D0 (en) Treatment
GB8716536D0 (en) Treatment
GB8726982D0 (en) Treatment
GB8726981D0 (en) Treatment